SLC7A11 and neoplasm: We recently demonstrated the utility of the tumour explant model to test the therapeutic effects of inhibiting SLC7A11 using either an siRNA-nanomedicine or a clinical-grade SLC7A11 inhibitor, sulfasalazine [95].